☰

Kenneth D. Aldape, MD PhD - Publications

Affiliations: 
Pathology University of Texas MD Anderson Cancer Center, Houston, TX, United States 
Website:
http://www2.mdanderson.org/app/peoplefinder/person.cfm?id=3D5CDFD8C91C
Tree Info Grants Similar researchers PubMed Report error

338 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Andreiuolo F, Ferrone CK, Rajan S, Perry A, Guney E, Cham E, Giannini C, Toland A, Willard N, de Souza AS, Dazelle K, Chung HJ, Singh O, Conway K, Coley N, ... ... Aldape K, et al. Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion. Acta Neuropathologica Communications. 12: 42. PMID 38500181 DOI: 10.1186/s40478-024-01746-7  0.319
2023 Malta TM, Sabedot TS, Morosini NS, Datta I, Garofano L, Vallentgoed WR, Varn FS, Aldape K, D'Angelo F, Bakas S, Barnholtz-Sloan JS, Gan HK, Hasanain M, Hau AC, Johnson KC, et al. The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen. Cancer Research. PMID 38117484 DOI: 10.1158/0008-5472.CAN-23-2093  0.326
2023 Bogumil H, Sill M, Schrimpf D, Ismer B, Blume C, Rahmanzade R, Hinz F, Cherkezov A, Banan R, Friedel D, Reuss DE, Selt F, Ecker J, Milde T, Pajtler KW, ... ... Aldape K, et al. Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions. Acta Neuropathologica. PMID 36933012 DOI: 10.1007/s00401-023-02558-0  0.311
2023 Pun M, Pratt D, Nano PR, Joshi PK, Jiang L, Englinger B, Rao A, Cieslik M, Chinnaiyan AM, Aldape K, Pfister S, Filbin MG, Bhaduri A, Venneti S. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Acta Neuropathologica Communications. 11: 25. PMID 36759899 DOI: 10.1186/s40478-023-01514-z  0.311
2022 Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H, Nasrallah MP, Santi M, Fernandes IL, Nirschl J, Dahiya S, Neill S, ... ... Aldape K, et al. Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathologica. PMID 36271929 DOI: 10.1007/s00401-022-02513-5  0.3
2022 Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, Lee I, Raffeld M, Gilbert MR, Armstrong TS, Pytel P, Borys E, Klonoski JM, McCord M, Horbinski C, ... ... Aldape K, et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathologica. PMID 35103816 DOI: 10.1007/s00401-022-02404-9  0.311
2021 Sievers P, Henneken SC, Blume C, Sill M, Schrimpf D, Stichel D, Okonechnikov K, Reuss DE, Benzel J, Maaß KK, Kool M, Sturm D, Zheng T, Ghasemi DR, Kohlhof-Meinecke P, ... ... Aldape K, et al. Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica. PMID 34355256 DOI: 10.1007/s00401-021-02356-6  0.308
2020 Yu G, Butler MK, Abdelmaksoud A, Pang Y, Su YT, Rae Z, Dadkhah K, Kelly MC, Song YK, Wei JS, Terabe M, Atony R, Mentges K, Theeler BJ, Penas-Prado M, ... ... Aldape K, et al. Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology. 10: 601452. PMID 33520712 DOI: 10.3389/fonc.2020.601452  0.302
2020 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, ... ... Aldape K, et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902983. PMID 32706640 DOI: 10.1200/Jco.19.02983  0.356
2020 Nassiri F, Chakravarthy A, Feng S, Shen SY, Nejad R, Zuccato JA, Voisin MR, Patil V, Horbinski C, Aldape K, Zadeh G, De Carvalho DD. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nature Medicine. PMID 32572265 DOI: 10.1038/S41591-020-0932-2  0.355
2020 Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ, Hawkins C, Merchant T, Pajtler K, Venneti S, Louis DN. cIMPACT-NOW Update 7: advancing the molecular classification of ependymal tumors. Brain Pathology (Zurich, Switzerland). PMID 32502305 DOI: 10.1111/Bpa.12866  0.391
2020 Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. MGMT Status as a Clinical Biomarker in Glioblastoma. Trends in Cancer. 6: 380-391. PMID 32348734 DOI: 10.1016/J.Trecan.2020.02.010  0.361
2020 Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, ... ... Aldape K, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine. PMID 32341580 DOI: 10.1038/S41591-020-0827-2  0.308
2020 Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, ... ... Aldape KD, et al. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-Oncology. PMID 32328653 DOI: 10.1093/Neuonc/Noaa106  0.344
2020 Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathology (Zurich, Switzerland). PMID 32307792 DOI: 10.1111/Bpa.12832  0.371
2020 Fukuoka K, Mamatjan Y, Tatevossian R, Zapotocky M, Ryall S, Stucklin AG, Bennett J, Nobre LF, Arnoldo A, Luu B, Wen J, Zhu K, Leon A, Torti D, Pugh TJ, ... ... Aldape K, et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas. Neuro-Oncology. PMID 32242226 DOI: 10.1093/Neuonc/Noaa077  0.368
2020 Pratt D, Quezado M, Abdullaev Z, Hawes D, Yang F, Garton HJL, Judkins AR, Mody R, Chinnaiyan A, Aldape K, Koschmann C, Venneti S. Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Acta Neuropathologica Communications. 8: 37. PMID 32197665 DOI: 10.1186/S40478-020-00905-W  0.352
2020 El-Sehemy A, Selvadurai HJ, Ortin-Martinez A, Pokrajac NT, Mamatjan Y, Tachibana N, Rowland KJ, Lee L, Park NI, Aldape KD, Dirks P, Wallace VA. Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and WNT. The Journal of Clinical Investigation. PMID 32182224 DOI: 10.1172/Jci128994  0.411
2020 Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, et al. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. PMID 32154928 DOI: 10.1002/Cncr.32811  0.323
2019 Karimi S, Zuccato JA, Mamatjan Y, Mansouri S, Suppiah S, Nassiri F, Diamandis P, Munoz DG, Aldape KD, Zadeh G. The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. Clinical Epigenetics. 11: 185. PMID 31806041 DOI: 10.1186/S13148-019-0766-2  0.385
2019 Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. PMID 31748746 DOI: 10.1038/S41586-019-1775-1  0.382
2019 Fukuoka K, Mamatjan Y, Ryall S, Komosa M, Bennett J, Zapotocky M, Keith J, Myrehaug S, Hazrati LN, Aldape K, Laperriere N, Bouffet E, Tabori U, Hawkins C. BRAF V600E mutant oligodendroglioma-like tumors with chromosomal instability in adolescents and young adults. Brain Pathology (Zurich, Switzerland). PMID 31630459 DOI: 10.1111/Bpa.12799  0.385
2019 Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, Gepfner-Tuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, ... ... Aldape KD, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology. PMID 31158293 DOI: 10.1093/Neuonc/Noz061  0.332
2019 Papaioannou MD, Djuric U, Kao J, Karimi S, Zadeh G, Aldape K, Diamandis P. Proteomic analysis of meningiomas reveals clinically-distinct molecular patterns. Neuro-Oncology. PMID 31077268 DOI: 10.1093/Neuonc/Noz084  0.342
2019 Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, von Deimling A, Wesseling P. cIMPACT-NOW: A practical summary of diagnostic points from Round 1 updates. Brain Pathology (Zurich, Switzerland). PMID 31038238 DOI: 10.1111/Bpa.12732  0.35
2019 Bunda S, Heir P, Metcalf J, Li ASC, Agnihotri S, Pusch S, Yasin M, Li M, Burrell K, Mansouri S, Singh O, Wilson M, Alamsahebpour A, Nejad R, Choi B, ... ... Aldape K, et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nature Communications. 10: 661. PMID 30737375 DOI: 10.1038/S41467-018-08087-9  0.348
2019 Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougère C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF. Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology. 21: i44-i61. PMID 30649491 DOI: 10.1093/Neuonc/Noy143  0.322
2019 Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, ... ... Aldape K, et al. Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology. 21: i18-i31. PMID 30649489 DOI: 10.1093/Neuonc/Noy136  0.326
2019 Mamatjan Y, Cabanero M, Weiss J, Zuccato J, Sorotsky H, Tsao MS, Aldape KD, Zadeh G, Shepherd FA. Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis. Journal of Clinical Oncology. 37: e20574-e20574. DOI: 10.1200/Jco.2019.37.15_Suppl.E20574  0.313
2019 Welsh J, Aldape K, Jones J. Abstract PL04-02: Extracellular vesicles as opportunities for integrative or focused liquid biopsy studies Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-Pl04-02  0.322
2019 Suppiah S, Liu J, Wei Q, Mamatjan Y, Heir P, Nassiri F, Mansouri S, Aldape K, Zadeh G. Integrated Multi-Omics Characterization of Neurofibromatosis Type 1 Related Peripheral Nerve Sheath Tumors Identifies Two Distinct Malignant Peripheral Nerve Sheath Tumors Subtypes with Sonic Hedgehog or WNT Pathway Activation Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_138  0.312
2019 Bent MJVD, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Wick W, Clement PM, Baurain J, Mason WP, Wheeler H, Weller M, Aldape KD, Wesseling P, Kros JM, et al. Second Interim And First Molecular Analysis Of The Eortc Randomized Phase Iii Intergroup Catnon Trial On Concurrent And Adjuvant Temozolomide In Anaplastic Glioma Without 1P/19Q Codeletion Neuro-Oncology. 21: 3-3. DOI: 10.1093/Neuonc/Noz126.006  0.319
2018 Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, De Mello RA, Dias J, Huntsman D, Hermanns T, Wild PJ, ... ... Aldape K, et al. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. The Journal of Clinical Investigation. PMID 30358567 DOI: 10.1172/Jci121303  0.318
2018 Agnihotri S, Mansouri S, Burrell K, Li M, Mamatjan Y, Liu JC, Nejad R, Kumar S, Jalali S, Singh S, Vartanian A, Chen EX, Karimi S, Singh O, Bunda S, ... ... Aldape K, et al. Ketoconazole and Posaconazole Selectively Target HK2 Expressing Glioblastoma Cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30322879 DOI: 10.1158/1078-0432.Ccr-18-1854  0.337
2018 Glowacka WK, Jain H, Okura M, Maimaitiming A, Mamatjan Y, Nejad R, Farooq H, Taylor MD, Aldape K, Kongkham P. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. Acta Neuropathologica. PMID 29428975 DOI: 10.1007/S00401-018-1821-3  0.354
2018 Sloan AE, Gilbert MR, Zhang P, Aldape KD, Wu J, Rogers LR, Wen PY, Barani IJ, Iwamoto FM, Raval RR, Voloschin AD, Groot JFD, Won M, Mehta MP. NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology. 36: 2053-2053. DOI: 10.1200/Jco.2018.36.15_Suppl.2053  0.307
2018 Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats I, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, De Groot JF, Yung WKA, et al. Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma. Journal of Clinical Oncology. 36: 2044-2044. DOI: 10.1200/Jco.2018.36.15_Suppl.2044  0.308
2018 Glowacka W, Jain H, Okura M, Maimaitiming A, Nejad R, Yasin M, Farooq H, Aldape K, Kongkham P. Abstract 5325: 5-hydroxymethylcytosine profiling identifies differential targeting in IDH1 mutant versus IDH1 wild-type high-grade gliomas Cancer Research. 78: 5325-5325. DOI: 10.1158/1538-7445.Am2018-5325  0.381
2018 Mamatjan Y, Bunda S, Moraes F, Suppiah S, Heir P, Maimaitiming A, Zadeh G, Aldape K. PATH-25. SURVIVAL STRATIFICATION OF IDH MUTANT GLIOMA USING METHYLATION AND mRNA ANALYSIS OF HOX GENES Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.681  0.302
2018 Karimi S, Suppiah S, Mansouri S, Nassiri F, Mamatjan Y, Liu J, Aldape K, Zadeh G. Mngi-12. Expression Of Programmed Cell Death Ligand-1 (Pd-L1) In Meningioma: Clinical Utility For Prediction Of Tumor Recurrence And Association With Hypoxic Response And Nfkb2 Activation Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.628  0.313
2018 Suppiah S, Karimi S, Mansouri S, Mamatjan Y, Liu J, Aldape K, Zadeh G. Gene-26. Molecular Characterization Of Benign And Malignant Peripheral Nerve Sheath Tumors That Occur In Sporadic And Syndromic Settings Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.452  0.313
2018 Velásquez C, Mansouri S, Molinedo P, Martino J, Mamatjan Y, Talamillo A, Karimi S, Terán N, Aldape K, Zadeh G, Fernández-Luna J. Gene-05. Upregulation Of Odz1-Mediated Invasion In The Hypoxic Tumor Microenvironment In Glioblastoma Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.432  0.365
2018 Nejad R, Nassiri F, Mamatjan Y, Sim H, Chen E, Agnihotri S, Aldape K, Zadeh G. Cbmt-06. Lower Grade Isocitrate Dehydrogenase (Idh) Mutant Gliomas Metabolically Mimicking Glioblastoma (Gbm) Express Higher R:S 2-Hydroxyglutarate Ratios Relative To Non-Gbm-Mimicking Idh Mutant Gliomas Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.125  0.301
2018 Fukuoka K, Mamatjan Y, Tatevossian R, Zapotocky M, Ryall S, Stucklin AG, Benett J, Luu B, Wen J, Hazrati L, Laperriere N, Drake J, Rutka J, Dirks P, Kulkarni A, ... ... Aldape K, et al. LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS Neuro-Oncology. 20: i106-i106. DOI: 10.1093/Neuonc/Noy059.352  0.315
2018 Mansouri S, Velasquez C, Nassiri F, Wilson MR, Suppiah S, Moraes F, Metcalf J, Tung T, Singh O, Mansouri A, Aldape K, Zadeh G. 53 Alterations in the epigenetic profile of glioblastoma tumors within hypoxic tumor regions Canadian Journal of Neurological Sciences. 45. DOI: 10.1017/Cjn.2018.292  0.371
2018 Karimi S, Suppiah S, Nassiri F, Mamatjan Y, Liu J, Zadeh G, Aldape K. 40 Prognostic significance of PD-L1 expression in meningioma for tumor recurrence; associated with hypoxia and NFKB2 activation Canadian Journal of Neurological Sciences. 45. DOI: 10.1017/Cjn.2018.281  0.321
2017 Mamatjan Y, Agnihotri S, Goldenberg A, Tonge P, Mansouri S, Zadeh G, Aldape K. Molecular Signatures for Tumor Classification An Analysis of TCGA Data. The Journal of Molecular Diagnostics : Jmd. PMID 28867603 DOI: 10.1016/J.Jmoldx.2017.07.008  0.361
2017 Karimi S, Vyas MV, Gonen L, Tabasinejad R, Ostrom Q, Barnholtz-Sloan J, Suppiah S, Zadeh G, Aldape K. Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. Neuro-Oncology. PMID 28531342 DOI: 10.1093/Neuonc/Nox089  0.389
2017 van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology. PMID 28339700 DOI: 10.1093/Neuonc/Now277  0.383
2017 Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathologica. PMID 28130639 DOI: 10.1007/S00401-017-1678-X  0.375
2017 Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Shamanna RK, et al. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. PMID 28125801 DOI: 10.18632/Oncotarget.14802  0.302
2017 Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology. PMID 28116649 DOI: 10.1007/S11060-016-2357-9  0.328
2017 Sim H, Nejad R, Zhang W, Mason WP, Bernstein M, Aldape K, Zadeh G, Chen EX. Comparison of 2-hydroxyglutarate (2HG) levels in tissue and serum of isocitrate dehydrogenase (IDH)-mutated (MUT) versus wild-type (WT) gliomas. Journal of Clinical Oncology. 35: 2037-2037. DOI: 10.1200/Jco.2017.35.15_Suppl.2037  0.332
2017 Xie Q, Han D, Faust K, Aldape K, Zadeh G, Volynskaya Z, Djuric U, Diamandis P. Path-46. Automated Histopathologic Classification Of Brain Tumors Using Artificial Intelligence Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.736  0.341
2017 Suppiah S, Agnihotri S, Yasin M, Zadeh G, Aldape K, Liu J. Mngi-04. Pathway Analysis Of Radiation-Induced Meningiomas Reveals Upregulation Of Inflammatory Pathways In Tumors With Nf2-Fusion Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.543  0.325
2017 Mansouri S, Burrell K, Yasin M, Agnihotri S, Nejad R, Zhao T, Aldape K, Zadeh G. Tmic-16. The Immuno-Protective Function Of Glioma-Associated Bone Marrow Derived Cells Depends On The Stage Of Tumor Growth And Is Influenced By Treatment With Minocycline Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.1006  0.315
2017 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, Fleming J, McElroy JP, Timmers CD, Becker AP, ... ... Aldape K, et al. ACTR-37. PREDICTIVE SIGNIFICANCE OF IDH1/2 MUTATION AND 1p/19q CO-DELETION STATUS IN A POST-HOC ANALYSIS OF NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 19: vi8-vi8. DOI: 10.1093/Neuonc/Nox168.028  0.326
2017 Nejad R, Sim H, Aldape K, Mason W, Bernstein M, Gentili F, Kalia S, Tung T, Chen E, Zadeh G. P10.21 2-hydroxyglutarate as a biomarker for IDH mutation in low grade gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.339  0.305
2017 Agnihotri S, Wilson M, Jalali S, Li M, Pagnotta S, Iavarone A, Aldape K, Zadeh G. OS08.7 The somatic landscape of Schwannoma. Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.057  0.388
2017 Bell EH, Zhang P, Aldape K, McElroy J, Mehta M, Fleming J, Liu Z, Coons S, Johnson D, Chakravarti A. OS01.7 MGMT promoter methylation status independently predicts progression-free survival in NRG Oncology/RTOG 9802: a phase III trial of RT vs RT + PCV in high-risk low-grade gliomas Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox036.006  0.332
2016 Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, et al. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathology (Zurich, Switzerland). PMID 27997995 DOI: 10.1111/Bpa.12457  0.358
2016 Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, et al. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica. PMID 27909809 DOI: 10.1007/S00401-016-1646-X  0.365
2016 Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, ... ... Aldape KD, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica. PMID 27858204 DOI: 10.1007/S00401-016-1643-0  0.325
2016 Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. Journal of Neuro-Oncology. PMID 27770279 DOI: 10.1007/S11060-016-2288-5  0.309
2016 Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, Landon-Brace N, Tung T, Dowar M, Li T, Bruce JP, ... ... Aldape KD, et al. The genomic landscape of schwannoma. Nature Genetics. PMID 27723760 DOI: 10.1038/Ng.3688  0.359
2016 Aldape K, Nejad R, Louis DN, Zadeh G. Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. Neuro-Oncology. PMID 27688263 DOI: 10.1093/Neuonc/Now181  0.344
2016 Bell EH, McElroy JP, Fleming J, Timmers C, Chakraborty AR, Salavaggione AL, Chang SM, Shaw EG, Aldape K, Brachman D, Schultz CJ, Shih HA, Curtis M, Hunter GK, Murtha AD, et al. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. International Journal of Radiation Oncology, Biology, Physics. 96: S91. PMID 27676051 DOI: 10.1016/J.Ijrobp.2016.06.229  0.32
2016 Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taconne MS, Golbourn B, Aldape KD, Zadeh G. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget. PMID 27588472 DOI: 10.18632/Oncotarget.11680  0.385
2016 Mansouri S, Singh S, Alamsahebpour A, Burrell K, Li M, Karabork M, Ekinci C, Koch E, Solaroglu I, Chang JT, Wouters B, Aldape K, Zadeh G. DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma. Oncotarget. PMID 27421140 DOI: 10.18632/Oncotarget.10570  0.367
2016 Johann PD, Hovestadt V, Thomas C, Jeibmann A, Heß K, Bens S, Oyen F, Hawkins C, Pierson CR, Aldape K, Pyo Kim S, Widing E, Sumerauer D, Hauser P, van Landeghem F, et al. Cribriform neuroepithelial tumor (crinet): Molecular characterization of a smarcb1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathology (Zurich, Switzerland). PMID 27380723 DOI: 10.1111/Bpa.12413  0.418
2016 Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. Journal of Neuro-Oncology. PMID 27270908 DOI: 10.1007/S11060-016-2157-2  0.353
2016 Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, Zadeh G. Sox2: regulation of expression and contribution to brain tumors Cns Oncology. 5: 159-173. PMID 27230973 DOI: 10.2217/Cns-2016-0001  0.398
2016 LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH, ... ... Aldape K, et al. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro-Oncology. PMID 27179361 DOI: 10.1093/Neuonc/Now051  0.36
2016 Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen H. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. American Journal of Clinical Pathology. 145: 222-237. PMID 27124905 DOI: 10.1093/Ajcp/Aqv023  0.302
2016 Aldape K, Pfister SM. Next-generation molecular diagnostics Handbook of Clinical Neurology. 134: 121-130. PMID 26948351 DOI: 10.1016/B978-0-12-802997-8.00007-4  0.346
2016 Zadeh G, Aldape K. Bringing IDH into the Fold Cancer Cell. 29: 139-140. PMID 26859452 DOI: 10.1016/J.Ccell.2016.01.010  0.312
2016 Mansouri A, Klironomos G, Taslimi S, Kilian A, Gentili F, Khan OH, Aldape K, Zadeh G. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. Journal of Neurosurgery. 125: 431-40. PMID 26722844 DOI: 10.3171/2015.7.Jns15546  0.341
2016 Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, ... ... Aldape KD, et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute. 108. PMID 26668184 DOI: 10.1093/Jnci/Djv377  0.344
2016 Bent MJVD, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Wick W, Clement PM, Baurain J, Mason WP, Wheeler H, Chinot OL, Weller M, Golfinopoulos V, Aldape K, et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba2000  0.364
2016 Sim H, Zadeh G, Mason WP, Aldape K, Bernstein M, Gentili F, Hodaie M, Kalia S, Kongkham PN, Zhang W, Tung T, Chen EX. Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues. Journal of Clinical Oncology. 34: 2028-2028. DOI: 10.1200/Jco.2016.34.15_Suppl.2028  0.309
2016 Bell EH, McElroy JP, Fleming J, Timmers CD, Chakraborty AR, Salavaggione AL, Shaw EG, Aldape KD, Brachman D, Murtha AD, Won M, Mehta MP, Chakravarti A. Comprehensive mutation analysis in NRG Oncology/RTOG 9802: A phase III study of RT vs RT + PCV in high-risk low-grade gliomas (LGGs). Journal of Clinical Oncology. 34: 2017-2017. DOI: 10.1200/Jco.2016.34.15_Suppl.2017  0.328
2016 Bell EH, McElroy JP, Fleming J, Timmers CD, Chakraborty AR, Salavaggione AL, Chang SM, Aldape KD, Brachman D, Shih HA, Zhang P, Mehta MP, Chakravarti A. Comprehensive mutation analysis in NRG Oncology/RTOG 9813: A phase III trial of RT + TMZ vs RT + nu for anaplastic astrocytoma and mixed anaplastic oligoastrocytoma (Astrocytoma Dominant). Journal of Clinical Oncology. 34: 2016-2016. DOI: 10.1200/Jco.2016.34.15_Suppl.2016  0.324
2016 Zhang L, Zhang S, Yao J, Lowery FJL, Zhang Q, Huang W, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty J, Palmieri D, ... ... Aldape K, et al. Abstract 907: Brain microenvironment induced PTEN loss by microRNAs promotes brain metastasis Cancer Research. 76: 907-907. DOI: 10.1158/1538-7445.Am2016-907  0.357
2016 Wang Q, Ezhilarasan R, Eskilsson E, Gumin J, Yang J, Jaffari M, Tang M, Aldape KD, Lang FF, Verhaak RGW, Sulman EP. Abstract 1646: A glioblastoma methylation assay (GaMA) developedfrom genomic analysis of glioma spheroid cultures predicts response toradiation therapy in patients with glioblastoma Cancer Research. 76: 1646-1646. DOI: 10.1158/1538-7445.Am2016-1646  0.344
2016 Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty A, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, et al. Mpth-41. Mgmt Status Predicts Survival Outcomes In Nrg Oncology/Rtog 0424: A Phase Ii Trial Of Temozolomide-Based Chemoradiotherapy For High Risk Low-Grade Gliomas Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.478  0.308
2016 Chen H, Thomas C, Munoz FA, Alexandrescu S, Horbinski C, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Iafrate AJ, Golfinos J, Chi A, et al. MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS Neuro-Oncology. 18: vi113-vi113. DOI: 10.1093/Neuonc/Now212.471  0.357
2016 Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Coons SW, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming J, Chakraborty A, Becker AP, ... Aldape KD, et al. MPTH-06. 1p/19q CO-DELETION STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RT VS RT + PCV IN HIGH RISK LOW-GRADE GLIOMAS Neuro-Oncology. 18: vi106-vi106. DOI: 10.1093/Neuonc/Now212.444  0.32
2016 Mansouri S, Singh S, Alamsahebpour A, Burrell K, Li M, Karabork M, Ekinci C, Solaroglu I, Chang JT, Aldape K, Zadeh G. PS2 - 197 DICER Governs Characteristics of Glioma Stem Cells and the Resulting Tumors in Xenograft Mouse Models of GBM Canadian Journal of Neurological Sciences. 43. DOI: 10.1017/Cjn.2016.371  0.352
2015 Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, ... ... Aldape K, et al. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. American Journal of Epidemiology. PMID 26656478 DOI: 10.1093/Aje/Kwv235  0.334
2015 Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, ... ... Aldape K, et al. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 15097-112. PMID 26558781 DOI: 10.1523/Jneurosci.1265-15.2015  0.339
2015 Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, ... ... Aldape K, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/S11060-015-1958-Z  0.387
2015 Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget. 6: 31007-17. PMID 26307681 DOI: 10.18632/Oncotarget.5219  0.313
2015 Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathologica Communications. 3: 34. PMID 26091668 DOI: 10.1186/S40478-015-0213-3  0.388
2015 Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, ... ... Aldape K, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica. PMID 26087904 DOI: 10.1007/S00401-015-1454-8  0.412
2015 Demicco EG, Wani K, Fox PS, Bassett RL, Young ED, Lev D, Aldape KD, Lazar AJ, Wang WL. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Human Pathology. 46: 1015-26. PMID 25976141 DOI: 10.1016/J.Humpath.2015.03.014  0.393
2015 Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, ... ... Aldape K, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica. 129: 867-73. PMID 25962792 DOI: 10.1007/S00401-015-1438-8  0.333
2015 Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica. 129: 829-48. PMID 25943888 DOI: 10.1007/S00401-015-1432-1  0.419
2015 Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. Journal of the Neurological Sciences. 353: 92-7. PMID 25934342 DOI: 10.1016/J.Jns.2015.04.014  0.306
2015 Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget. 6: 10016-29. PMID 25881542 DOI: 10.18632/Oncotarget.3540  0.352
2015 Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. The Oncologist. 20: 466-73. PMID 25802405 DOI: 10.1634/Theoncologist.2014-0107  0.323
2015 Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, Jhangiani SN, Plon SE, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, ... ... Aldape K, et al. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Scientific Reports. 5: 8278. PMID 25652157 DOI: 10.1038/Srep08278  0.303
2015 Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJ. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. The American Journal of Surgical Pathology. 39: 454-61. PMID 25634750 DOI: 10.1097/Pas.0000000000000325  0.324
2015 Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, Lewis L, Tombrello J, Tsavachidis S, Liu Y, Jalali A, Plon SE, Lau CC, Parsons DW, Claus EB, ... ... Aldape K, et al. Germline mutations in shelterin complex genes are associated with familial glioma. Journal of the National Cancer Institute. 107: 384. PMID 25482530 DOI: 10.1093/Jnci/Dju384  0.305
2015 Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, ... ... Aldape KD, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. The Journal of Investigative Dermatology. 135: 508-15. PMID 25148578 DOI: 10.1038/Jid.2014.366  0.335
2015 Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, et al. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology. 17: 440-7. PMID 25121770 DOI: 10.1093/Neuonc/Nou162  0.352
2015 Jalali S, Singh S, Agnihotri S, Wataya T, Salehi F, Alkins R, Burrell K, Navab R, Croul S, Aldape K, Zadeh G. A role for matrix remodelling proteins in invasive and malignant meningiomas. Neuropathology and Applied Neurobiology. 41: e16-28. PMID 24989599 DOI: 10.1111/Nan.12166  0.31
2015 Mandel JJ, Cachia D, Liu DD, Aldape KD, Fuller G, Groot JFD. IDH1 mutation status and outcome in clinical trials for recurrent glioblastoma. Journal of Clinical Oncology. 33: 2073-2073. DOI: 10.1200/Jco.2015.33.15_Suppl.2073  0.322
2015 Chang SM, Zhang P, Cairncross JG, Gilbert MR, Bahary J, Dolinskas C, Aldape KD, Chakravarti A, Schiff D, Jaeckle KA, Brown PD, Barger G, Werner-Wasik M, Shih HA, Brachman D, et al. Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). Journal of Clinical Oncology. 33: 2002-2002. DOI: 10.1200/Jco.2015.33.15_Suppl.2002  0.367
2015 Olar A, Wani K, Diefes K, Heathcock L, Thuijl Hv, Gilbert M, Armstrong T, Sulman E, Cahill D, Reijneveld J, Ylstra B, Wesseling P, Aldape K. Abstract 5270: IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas Cancer Research. 75: 5270-5270. DOI: 10.1158/1538-7445.Am2015-5270  0.402
2015 Wang Q, Ezhilarasan R, Goodman LD, Gumin J, Zheng S, Yoshihara K, Sun P, Yang J, Heffernan T, Draetta G, Aldape KD, Lang FF, Verhaak RGW, Sulman EP. Abstract 4795: A novel gene fusion in glioblastoma and a radiation response methylation signature identified by genomic characterization of glioma sphere-forming cells Cancer Research. 75: 4795-4795. DOI: 10.1158/1538-7445.Am2015-4795  0.451
2015 Tonge P, Agnihotri S, Li M, Metcalf J, Bernstein M, Zadeh G, Aldape K. STEM-20MAPPING DYNAMICS OF CELL DIVISION AND GENE EXPRESSION AT THE SINGLE CELL LEVEL TO UNDERSTAND GLIOMA CELL STATES Neuro-Oncology. 17: v212.2-v212. DOI: 10.1093/Neuonc/Nov234.20  0.351
2015 Olar A, Goodman L, Wani K, Boehling N, DeMonte F, Aldape K, Sulman E. Mpth-25An 18-Gene Expression Signature Predicts Recurrence-Free Survival In Meningioma Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov222.25  0.396
2015 Nejad R, Louis DN, Aldape K, Zadeh G. Mpth-22Integrating Molecular Markers Into The World Health Organization (Who) Classification Of Gliomas: Survey Results From The Sno Membership Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov222.22  0.376
2015 Zadeh G, Aldape K, Li M, Agnihotri S, Burrell K, Vartanian A, Alamsahebpour A, Jalali S. Metb-08Inhibition Of Hexokinase 2 Using Tumor Glycolysis Inhibitors Identified Through A Drug Screen Inhibits Glioblastoma Growth In Vitro And In Vivo Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov221.08  0.374
2015 Eskilsson E, Wang Q, Ezhilarasan R, Bhat KP, Tang M, Goodman LD, Aldape KD, Verhaak RG, Sulman EP. Epig-05Radioresistance Of Podoplanin-Expressing Glioma Stem Cells Is Associated With Ezh2-Driven Polycomb Repressive Complex Activity Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.05  0.38
2015 Mansouri S, Singh S, Burrell K, Li M, Alamsahebpour A, Aldape K, Zadeh G. CBIO-22DICER AND miRNAs REGULATE GLIOMA STEM CELL CHARACTERISTICS Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov209.22  0.324
2015 Jalali S, Burrows F, Trikha M, Zadeh G, Aldape K. Cbio-14Targeting Proteasome Activity With Marizomib As A Therapeutic Perspective For Glioma Patients Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov209.14  0.437
2015 Jaeckle K, Vogelbaum M, Ballman K, Giannini C, Aldape K, Cerhan J, Wefel J, Nordstrom D, Jenkins R, Klein M, Raizer J, van den Bent M, Wick W, Flynn P, Dhermain F, et al. ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN Neuro-Oncology. 17: v4.4-v5. DOI: 10.1093/Neuonc/Nov206.16  0.31
2015 Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas C, Aldape KD, Bell E, Sciff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, et al. ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA) Neuro-Oncology. 17: v3.4-v3. DOI: 10.1093/Neuonc/Nov206.12  0.368
2015 Pajtler KW, Witt H, Sill M, Jones D, Hovestadt V, Johann P, Reimand J, Lichter P, Taylor MD, Gilbertson R, Ellison DW, Aldape K, Korshunov A, Pfister SM, Kool M. Ep-03Molecular Classification Of Ependymal Tumors Across All Cns Compartments, Histopathological Grades And Age Groups Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov061.22  0.399
2014 Agnihotri S, Aldape KD, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurgical Focus. 37: E13. PMID 25434382 DOI: 10.3171/2014.9.Focus14505  0.403
2014 Huse JT, Aldape K. CMV and glioma--are we there yet? Neuro-Oncology. 16: 1433-4. PMID 25326550 DOI: 10.1093/Neuonc/Nou296  0.311
2014 Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, et al. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 5: 8937-46. PMID 25313136 DOI: 10.18632/ONCOTARGET.2339  0.33
2014 Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, Iyer A, Diefes KL, Aldape K, Berens M, Shen MM, Califano A. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell. 159: 402-14. PMID 25303533 DOI: 10.1016/J.Cell.2014.09.021  0.304
2014 Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 15: 1100-8. PMID 25163906 DOI: 10.1016/S1470-2045(14)70379-1  0.31
2014 Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Science Signaling. 7: ra75. PMID 25118327 DOI: 10.1126/Scisignal.2005196  0.352
2014 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 5: 3871-9. PMID 25003695 DOI: 10.18632/Oncotarget.2004  0.325
2014 Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, et al. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology. 16: 1541-6. PMID 24997140 DOI: 10.1093/Neuonc/Nou083  0.371
2014 Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Aldape K, Ye Y, Kurzrock R, Berry D. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4827-36. PMID 24987059 DOI: 10.1158/1078-0432.Ccr-14-0603  0.344
2014 Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. Journal of the Neurological Sciences. 344: 229-31. PMID 24980937 DOI: 10.1016/J.Jns.2014.06.023  0.308
2014 Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 5: 2208-20. PMID 24809734 DOI: 10.18632/Oncotarget.1893  0.384
2014 Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5537-46. PMID 24803579 DOI: 10.1158/1078-0432.Ccr-13-3003  0.309
2014 Kim BY, Jiang W, Beiko J, Prabhu SS, DeMonte F, Gilbert MR, Sawaya R, Aldape KD, Cahill DP, McCutcheon IE. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology. 118: 405-12. PMID 24777756 DOI: 10.1007/S11060-014-1451-0  0.401
2014 Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1634-5. PMID 24752060 DOI: 10.1200/Jco.2013.54.9717  0.334
2014 Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, Aldape KD, Zadeh G. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro-Oncology. 16: 1167-75. PMID 24642524 DOI: 10.1093/Neuonc/Nou035  0.421
2014 Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. American Journal of Clinical Pathology. 141: 559-72. PMID 24619758 DOI: 10.1309/Ajcp1Jugqmw7Zntl  0.347
2014 Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Plos One. 9: e91216. PMID 24614622 DOI: 10.1371/Journal.Pone.0091216  0.402
2014 Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, ... ... Aldape KD, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 506: 445-50. PMID 24553142 DOI: 10.1038/Nature13108  0.343
2014 Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, ... ... Aldape KD, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/Neuonc/Not247  0.375
2014 Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y, Lu Z. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Molecular Cell. 53: 75-87. PMID 24316223 DOI: 10.1016/J.Molcel.2013.11.001  0.32
2014 Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 16: 81-91. PMID 24305719 DOI: 10.1093/Neuonc/Not159  0.374
2014 Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/Neuonc/Not229  0.368
2014 Terashima K, Yu A, Chow WY, Hsu WC, Chen P, Wong S, Hung YS, Suzuki T, Nishikawa R, Matsutani M, Nakamura H, Ng HK, Allen JC, Aldape KD, Su JM, et al. Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors. Pediatric Blood & Cancer. 61: 593-600. PMID 24249158 DOI: 10.1002/Pbc.24833  0.39
2014 Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. The Journal of Pathology. 232: 165-77. PMID 24114756 DOI: 10.1002/Path.4282  0.362
2014 Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 32: 3509-3509. DOI: 10.1200/Jco.2014.32.15_Suppl.3509  0.345
2014 Boland GM, Piha-Paul SA, Subbiah V, Brusco L, Herbrich SM, Baggerly KA, Routbort M, Patel K, Luthra R, Naing A, Fu S, Falchook GS, Hong DS, Wheler JJ, Janku F, ... ... Aldape KD, et al. Clinical next-generation sequencing to identify actionable alterations in a phase I program. Journal of Clinical Oncology. 32: 11115-11115. DOI: 10.1200/Jco.2014.32.15_Suppl.11115  0.343
2014 Verhaak RGW, Cooper LAD, Salama SS, Aldape K, Yung WKA, Brat DJ. Abstract 936: Comprehensive and integrative genomic characterization of diffuse lower grade gliomas Cancer Research. 74: 936-936. DOI: 10.1158/1538-7445.Am2014-936  0.374
2014 Witt H, Sill M, Wani K, Mack S, Capper D, Heim S, Johann P, Lambert S, Rhyzova M, Hovestadt V, Tzaridis T, Pajtler K, Bender S, Milde T, Northcott PA, ... ... Aldape K, et al. Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups Cancer Research. 74: 3094-3094. DOI: 10.1158/1538-7445.Am2014-3094  0.42
2014 Jones DTW, Capper D, Sill M, Hovestadt V, Schweizer L, Fischer R, Schick M, Bewerunge-Hudler M, Benner A, Zagzag D, Lichter P, Karajannis MA, Aldape KD, Korshunov A, Deimling Av, et al. Abstract 1889: Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling Cancer Research. 74: 1889-1889. DOI: 10.1158/1538-7445.Am2014-1889  0.382
2014 Bell D, Sniegowski M, Wani K, Aldape K, Esmaeli B. Mutational landscape of lacrimal gland carcinomas and implications for treatment Pathology. 46. DOI: 10.1097/01.Pat.0000454491.09356.92  0.302
2014 Agnihotri S, Vartanian A, Burrell K, Singh S, Alamsahebpour A, Aldape K, Zadeh G. Tm-02Identification Of The Azole Class Of Antifungals As Potent Inhibitors Of Hexokinase Ii Mediated Tumour Metabolism In Glioblastoma. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou278.2  0.367
2014 Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Sawaya R, Weinberg J, Prabhu S, Fuller G, Aldape K, Fueyo J. Nt-18Phase I Clinical Trial Of Oncolytic Virus Delta-24-Rgd (Dnx-2401) With Biological Endpoints: Implications For Viro-Immunotherapy. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou265.17  0.411
2014 Burrell K, Singh S, Agnihotri S, Hill R, Aldape K, Zadeh G. Me-03Bone Marrow Derived Microglia And Their Function Within Tumor Microenvironment Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou261.2  0.369
2014 Agnihotri S, Burell K, Jalali S, Alamsahebpour A, Sabha N, Krischek B, Aldape K. MS-02TRANSCRIPTOME ANALYSIS IDENTIFIES THE PI3K/AKT/mTOR PATHWAY AS A TARGETABLE PATHWAY IN SCHWANNOMA Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou260.2  0.373
2014 Klironomos G, Larjani S, Mansouri A, Ghare A, Kilian A, Aldape K, Zadeh G. Ms-15The Impact Of Histopathologic And Radiologic Characteristics In Clinical Outcome Of Patients Who Underwent Surgery For Intracranial Meningiomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou260.14  0.412
2014 Yung WKA, Verhaak R, Cooper L, Salama S, Aldape K, Brat D. Ge-41Comprehensive And Integrative Genomic Characterization Of Diffuse Lower Grade Gliomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.40  0.37
2014 Olar A, Wani K, Mansouri A, Zadeh G, Wilson C, DeMonte F, Fuller G, Jones D, Pfister S, Deimling Av, Sulman E, Aldape K. EG-09EPIGENETIC PROFILING REVEALS A CpG HYPERMETHYLATION PHENOTYPE (CIMP) ASSOCIATED WITH WORSE PROGRESSION-FREE SURVIVAL IN MENINGIOMA. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou254.9  0.344
2014 Wani K, Armstrong TS, Jones DT, Vera-Bolanos E, Witt H, Capper D, Pfister SM, Gilbertson RJ, Gilbert MR, Aldape K. BI-30 * CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS Neuro-Oncology. 16: v30-v30. DOI: 10.1093/Neuonc/Nou239.30  0.355
2014 Burrell K, Singh S, Agnihotri S, Hill R, Aldape K, Zadeh G. Ai-05Impact Of Gbm Microenvironment On Expression Profile Of Bone Marrow Derived Progenitor Cells Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou238.5  0.358
2014 Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. At-07A Phase Ii Study Of Lapatinib And Dose-Dense Temozolomide (Tmz) For Adults With Recurrent Ependymoma: Patient Reported Outcomes (Pro) From A Cern Clinical Trial. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.7  0.316
2014 Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23  0.412
2014 Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung W, Sawaya R, Weinberg J, Prabhu S, Fuller G, Aldape K, Fueyo J. First-In-Human Phase I Clinical Trial Of Oncolytic Delta-24-Rgd (Dnx-2401) With Biological Endpoints: Implications For Viro- Immunotherapy Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.61  0.402
2014 Tabori U, Castelo-Branco P, Lee D, Gallo M, Limpan T, Mangerel J, Price A, Remke M, Zhang C, Heidari A, Wani K, Vanner R, Zadeh G, Karamchandani J, Das S, ... ... Aldape K, et al. Thor Methylation Provides Insight Into The Telomere Maintenance Landscape Of Malignant Gliomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.29  0.415
2014 Gomez-Manzano C, Gabrusiewicz K, Cortes-Santiago N, Hossain MB, Conrad C, Fuller G, Aldape K, Lang F, Gilbert M, Yung WKA, Fueyo J. Presence Of A Distinctive Myeloid Population Is Associated With The Invasive Tumor Phenotype Observed After Anti-Angiogenesis Therapies. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.53  0.381
2014 Sulman EP, Wang Q, Ezhilarasan R, Goodman LD, Gumen J, Sun P, Aldape K, Yung WA, Heffernan T, Draetta GF, Lang FF. The Treatment-Resistant Mesenchymal Signature In Glioblastoma Derives From Tumor Cells Independent Of Stroma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.28  0.425
2014 Aldape K, Zadeh G, Sulman E. Molecular-Based Grading In Idh-Mutant Lower Grade Gliomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.17  0.381
2014 Armstrong TS, Aldape K, Gajjar A, Haynes C, Hirakawa D, Gilbertson R, Gilbert MR. O8.10 * A MODEL FOR RESEARCH INITIATIVES FOR RARE CANCERS: THE COLLABORATIVE EPENDYMOMA RESEARCH NETWORK (CERN) Neuro-Oncology. 16: ii20-ii20. DOI: 10.1093/Neuonc/Nou174.71  0.309
2014 Zheng Y, Yang W, Aldape K, He J, Lu Z. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. Journal of Biological Chemistry. 289: 18667-18667. DOI: 10.1074/Jbc.A114.499020  0.322
2014 Agnihotri S, Burrell KE, Jalali S, Sabha N, Krischek B, Aldape KD, Zadeh G. Exploring Therapeutic Targets in Schwannoma Through Integrative Analysis Skull Base Surgery. 75. DOI: 10.1055/S-0034-1370542  0.388
2013 Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunology Research. 1: 112-22. PMID 24409449 DOI: 10.1158/2326-6066.Cir-13-0028  0.369
2013 Huse JT, Aldape KD. The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion On Medical Diagnostics. 7: 573-87. PMID 24161073 DOI: 10.1517/17530059.2013.846321  0.322
2013 Zheng Y, Yang W, Aldape K, He J, Lu Z. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. The Journal of Biological Chemistry. 288: 31488-95. PMID 24045955 DOI: 10.1074/Jbc.M113.499020  0.371
2013 Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, ... ... Aldape K, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nature Genetics. 45: 1141-9. PMID 23917401 DOI: 10.1038/Ng.2734  0.328
2013 Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Research. 73: 5764-74. PMID 23913825 DOI: 10.1158/0008-5472.Can-12-1803  0.319
2013 Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, Aldape KD, Lang FF, Tolias KF, McCarty JH. αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Molecular Biology of the Cell. 24: 474-82. PMID 23283986 DOI: 10.1091/Mbc.E12-07-0521  0.322
2013 Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E, Barrett L, Zhuang Y, Verma I, Benezra R, Aldape K, Iavarone A, et al. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. The Journal of Clinical Investigation. 123: 405-17. PMID 23241957 DOI: 10.1172/Jci63811  0.43
2013 Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, Aldape K, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. International Journal of Cancer. Journal International Du Cancer. 132: 509-20. PMID 22729867 DOI: 10.1002/Ijc.27690  0.335
2013 Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, De Groot JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, Yung WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM). Journal of Clinical Oncology. 31: TPS2106-TPS2106. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2106  0.302
2013 Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, ... ... Aldape KD, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Lba2010  0.361
2013 Sato M, Aldape KD, Mason CC, Diefes K, Heathcock L, Abegglen L, Schiffman JD, Colman H. Use of DNA copy number analysis of grade 2-4 gliomas to reveal differences in molecular ontogeny associated with IDH mutation status. Journal of Clinical Oncology. 31: 2026-2026. DOI: 10.1200/Jco.2013.31.15_Suppl.2026  0.329
2013 Raizer JJ, Giglio P, Hu JL, Groves MD, Merrell R, Conrad CA, Phuphanich S, Puduvalli VK, Loghin ME, Paleologos N, Yung WKA, Vaillant BD, Rudnick JD, Chamberlain MC, Vick N, ... ... Aldape KD, et al. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. Journal of Clinical Oncology. 31: 2019-2019. DOI: 10.1200/Jco.2013.31.15_Suppl.2019  0.395
2013 Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, Colman H, Chakravarti A, Jeraj R, Armstrong TS, Wefel JS, Brown PD, Jaeckle KA, Schiff D, Atkins JN, et al. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 31: 1-1. DOI: 10.1200/Jco.2013.31.15_Suppl.1  0.346
2013 Doucette T, Rao G, Aldape K, Wei J, Dziurzynski K, Rao A, Shen L, Gilbert MR, Heimberger AB. Abstract B82: Immune signatures of glioblastoma subtypes: Extrapolation from the Cancer Genome Atlas. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B82  0.362
2013 Colman H, Sato M, Mason CC, Diefes K, Heathcock L, Abegglen L, Aldape K, Schiffman JD. Abstract A08: Chromothripsis and gene-specific copy number aberrations associated with mutation of IDH1 in glioma Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A08  0.392
2013 Cahill DP, George A, Gilbert MR, Chakravarti A, Stupp R, Hegi M, Brown P, Jaeckle KA, Corn B, Sulman EP, Souhami L, Werner-Wasik M, Anderson BM, Mehta M, Aldape KD. Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A110  0.399
2012 Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Molecular Cell. 48: 771-84. PMID 23123196 DOI: 10.1016/J.Molcel.2012.09.028  0.312
2012 Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology. 14: 1511-8. PMID 23099651 DOI: 10.1093/Neuonc/Nos264  0.337
2012 Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current Treatment Options in Oncology. 13: 417-36. PMID 22956341 DOI: 10.1007/S11864-012-0210-8  0.399
2012 Amirian ES, Armstrong TS, Aldape KD, Gilbert MR, Scheurer ME. Predictors of survival among pediatric and adult ependymoma cases: a study using Surveillance, Epidemiology, and End Results data from 1973 to 2007. Neuroepidemiology. 39: 116-24. PMID 22846789 DOI: 10.1159/000339320  0.373
2012 Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro-Oncology. 14: 1136-45. PMID 22753228 DOI: 10.1093/Neuonc/Nos139  0.386
2012 Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-Oncology. 14: 761-7. PMID 22661585 DOI: 10.1093/Neuonc/Nos065  0.348
2012 Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Fuller GN. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Annals of Diagnostic Pathology. 16: 255-9. PMID 22445362 DOI: 10.1016/J.Anndiagpath.2011.11.003  0.336
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6  0.301
2012 Woodman SE, Lazar AJ, Aldape KD, Davies MA. New strategies in melanoma: molecular testing in advanced disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1195-200. PMID 22275506 DOI: 10.1158/1078-0432.Ccr-11-2317  0.332
2012 Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. Journal of Neuro-Oncology. 107: 487-501. PMID 22249692 DOI: 10.1007/S11060-011-0786-Z  0.356
2012 Li J, Sulman E, Aldape K. Molecular biology of brain tumors. Handbook of Clinical Neurology. 104: 23-34. PMID 22230432 DOI: 10.1016/B978-0-444-52138-5.00002-5  0.386
2012 Olar A, Raghunathan A, Albarracin CT, Aldape KD, Cahill DP, Powell SZ, Goodman JC, Fuller GN. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Annals of Diagnostic Pathology. 16: 161-70. PMID 22197544 DOI: 10.1016/J.Anndiagpath.2011.08.010  0.39
2012 Cahill DP, Beiko J, Suki D, Prabhu SS, Weinberg J, Lang FF, Gilbert MR, Rao G, McCutcheon IE, Aldape KD, Sawaya R. IDH1 status and survival benefit from surgical resection of enhancing and nonenhancing tumor in malignant astrocytomas. Journal of Clinical Oncology. 30: 2019-2019. DOI: 10.1200/Jco.2012.30.15_Suppl.2019  0.424
2012 Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, Groot JFD, Loghin ME, Puduvalli VK, Fisch M, Giglio P, Colman H, Conrad CA, Aldape KD, Yung WKA. Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 30: 2003-2003. DOI: 10.1200/Jco.2012.30.15_Suppl.2003  0.311
2012 Vaillant BD, Bhat K, Sulman EP, Balasubramaniyan V, Ezhilarasan R, Aldape KD, Colman H. The NF kappa B pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. Journal of Clinical Oncology. 30: 2002-2002. DOI: 10.1200/Jco.2012.30.15_Suppl.2002  0.411
2012 Chakravarti A, Wang M, Aldape KD, Sulman EP, Bredel M, Magliocco AM, Klimowicz AC, Hegi M, Stupp R, Gilbert MR, Curran WJ, Werner-Wasik M, Mahajan A, Schultz CJ, Mehta MP. A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. Journal of Clinical Oncology. 30: 2001-2001. DOI: 10.1200/Jco.2012.30.15_Suppl.2001  0.347
2012 Fueyo J, Conrad C, Gomez-Manzano C, Heimberger A, Vence L, Aldape K, Yung A, Sawaya R, Fuller G, Lang F. Abstract LB-123: Analyses of anti-cancer testis antigen antibodies in glioma patients treated with Delta-24 oncolytic adenovirus Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-123  0.397
2012 McCarthy DR, Diefes K, Aldape K, Maetzold D, Anderson K, Falk J, Hanna MM. Abstract 5545: MethyMeter®- A quantitative, bisulfite-free DNA methylation assay for improved clinical diagnostic and prognostic analysis of glioma biomarkers in FFPE tumor samples Cancer Research. 72: 5545-5545. DOI: 10.1158/1538-7445.Am2012-5545  0.365
2012 Kim S, Gonzalez N, Luthra R, Aldape K, Zuo Z, Liu P, Barron D, Kim KB. Abstract 4588: Frequency and clinical characteristics ofc-METmutation in malignant melanoma Cancer Research. 72: 4588-4588. DOI: 10.1158/1538-7445.Am2012-4588  0.332
2012 Joy AM, Ramesh A, Smirnov I, Misra A, Shapiro W, Phillips H, Aldape K, Mills G, Kim S, Feuerstein B. Abstract 3688: Akt pathway genes classify GBM into 6 prognostic subgroups with different clinical and molecular features Cancer Research. 72: 3688-3688. DOI: 10.1158/1538-7445.Am2012-3688  0.378
2012 Bhat KPL, Vaillant B, Balasubramainyan V, Ezhilarasan R, Hollingsworth F, James J, Wani K, Goodman L, Sulman E, Colman H, Aldape K. Abstract 3314: Phenotypic plasticity in glioma stem cells mediated by NFκB signaling Cancer Research. 72: 3314-3314. DOI: 10.1158/1538-7445.Am2012-3314  0.325
2012 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Gregory Cairncross J, Urgoiti GBR, Wen PY, Ligon KL, Schiff D, et al. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro-Oncology. 14: 677-678. DOI: 10.1093/Neuonc/Nos136  0.381
2011 Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2006. PMID 28023891 DOI: 10.1200/Jco.2011.29.15_Suppl.2006  0.368
2011 Vaillant BD, Bhat K, Sulman EP, Balasubramaniyan V, Wang S, Aldape KD, Colman H. CD44 as a prognostic and predictive marker for GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2049. PMID 28023811 DOI: 10.1200/Jco.2011.29.15_Suppl.2049  0.377
2011 Aldape KD, Wang M, Sulman EP, Hegi M, Colman H, Jones G, Chakravarti A, Mehta MP, Andrews DW, Long L, Diefes K, Heathcock L, Jenkins R, Schultz CJ, Gilbert MR, et al. RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: LBA2000. PMID 27937153 DOI: 10.1200/Jco.2011.29.18_Suppl.Lba2000  0.341
2011 Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. Bmc Medical Genomics. 4: 34. PMID 21489305 DOI: 10.1186/1755-8794-4-34  0.363
2011 de Groot JF, Sulman EP, Aldape KD. Multigene sets for clinical application in glioma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 449-56; quiz 457. PMID 21464148 DOI: 10.6004/Jnccn.2011.0040  0.421
2011 Cogdell D, Chung W, Liu Y, McDonald JM, Aldape K, Issa JP, Fuller GN, Zhang W. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. Chinese Journal of Cancer. 30: 247-53. PMID 21439246 DOI: 10.5732/Cjc.011.10025  0.421
2011 Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death & Disease. 2: e121. PMID 21368892 DOI: 10.1038/Cddis.2010.95  0.347
2011 Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, ... Aldape KD, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. The Journal of Clinical Investigation. 121: 161-73. PMID 21183793 DOI: 10.1172/Jci44798  0.346
2011 McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, Feychting M, Il'yasova D, Inskip PD, Johansen C, Melin BS, Ruder AM, Butler MA, Scheurer ME, Schüz J, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro-Oncology. 13: 242-50. PMID 21149253 DOI: 10.1093/Neuonc/Noq173  0.335
2011 Sulman EP, Aldape K. The use of global profiling in biomarker development for gliomas. Brain Pathology (Zurich, Switzerland). 21: 88-95. PMID 21129062 DOI: 10.1111/J.1750-3639.2010.00456.X  0.436
2011 Armstrong TS, Prabhu S, Aldape K, Hossan B, Kang S, Childress A, Tolentino L, Gilbert MR. A case of soft tissue metastasis from glioblastoma and review of the literature. Journal of Neuro-Oncology. 103: 167-72. PMID 20809248 DOI: 10.1007/S11060-010-0370-Y  0.374
2011 Fu J, Koul D, Yao J, Wang S, Gumin J, Shen R, Vaillant B, Colman H, Lang FF, Aldape KD, Yung WK. Abstract LB-114: Molecular and lineage analysis of glioblastoma stem cells identifies clinically relevant models of glioblatoma Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-114  0.378
2011 Bhat KPL, Salazar K, Vaillant B, Aldape K. Abstract 978: A regulatory role for TAZ in mesenchymal differentiation of glioblastoma Cancer Research. 71: 978-978. DOI: 10.1158/1538-7445.Am2011-978  0.411
2011 Galindo HG, Suraokar M, Behrens C, Woods DM, Kalhor N, Aldape KD, Fujimoto J, Herbst RS, Erickson HS, Wistuba II. Abstract 5166: Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis Cancer Research. 71: 5166-5166. DOI: 10.1158/1538-7445.Am2011-5166  0.342
2011 Goodman LD, Bhat K, Gumin J, Ezhilarasan R, Gao F, Love P, Colman H, Lang F, Aldape K, Sulman E. Abstract 3313: A proliferating population of glioma stem-like cells as characterized by expression of the cell surface glycoprotein CD58 Cancer Research. 71: 3313-3313. DOI: 10.1158/1538-7445.Am2011-3313  0.329
2011 Ezhilarasan R, Love PN, Goodman LD, Aldape KD, Sulman EP. Abstract 2467: Podoplanin expressing cancer stem cells show increased resistance to DNA damage induced by ionizing radiation Cancer Research. 71: 2467-2467. DOI: 10.1158/1538-7445.Am2011-2467  0.389
2010 Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (New York, N.Y.). 12: 748-54. PMID 20824051 DOI: 10.1593/Neo.10602  0.366
2010 Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Research. 70: 6697-703. PMID 20736378 DOI: 10.1158/0008-5472.Can-10-1271  0.309
2010 Fischer I, Aldape K. Molecular tools: biology, prognosis, and therapeutic triage. Neuroimaging Clinics of North America. 20: 273-82. PMID 20708546 DOI: 10.1016/J.Nic.2010.05.004  0.355
2010 Tchaicha JH, Mobley AK, Hossain MG, Aldape KD, McCarty JH. A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis. Oncogene. 29: 4460-72. PMID 20531304 DOI: 10.1038/Onc.2010.199  0.395
2010 Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR. Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro-Oncology. 12: 862-70. PMID 20511182 DOI: 10.1093/Neuonc/Noq009  0.421
2010 Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, Aldape K, Armstrong T, Houlston R, Hosking F, Robertson L, Xiao Y, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2467-74. PMID 20368557 DOI: 10.1200/Jco.2009.26.6213  0.302
2010 Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, Aldape KD, Gilbert MR, Bondy M. Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer. 116: 2242-9. PMID 20187096 DOI: 10.1002/Cncr.25006  0.327
2010 Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology. 12: 116-21. PMID 20150378 DOI: 10.1093/Neuonc/Nop020  0.379
2010 Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, ... ... Aldape K, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 12: 49-57. PMID 20150367 DOI: 10.1093/Neuonc/Nop007  0.357
2010 Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Research. 70: 453-62. PMID 20068170 DOI: 10.1158/0008-5472.Can-09-2189  0.4
2010 Wu A, Aldape K, Lang FF. High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. Journal of Neuro-Oncology. 99: 57-64. PMID 20035368 DOI: 10.1007/S11060-009-0100-5  0.349
2010 McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. Journal of Neurosurgery. 112: 925-33. PMID 19799498 DOI: 10.3171/2009.9.Jns09617  0.388
2010 Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/S11060-009-9948-7  0.42
2010 Liu D, Martin V, Fueyo J, Lee O, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype Oncotarget. 1: 700-709. DOI: 10.18632/Oncotarget.204  0.408
2010 Sulman EP, Guerrero M, Mikkelsen T, Bonato V, Phillips HS, Berger MS, Collins P, Broom B, Do K, Aldape KD. A mesenchymal/stem cell predictor of survival of patients with malignant gliomas. Journal of Clinical Oncology. 28: 2049-2049. DOI: 10.1200/Jco.2010.28.15_Suppl.2049  0.383
2010 Bredel M, Yadav A, Renfrow J, Scholtens D, Bredel C, Chandler J, Scheck A, Aldape KD, Chakravarti A, Harsh G. Deletion of NFKBIA in malignant gliomas. Journal of Clinical Oncology. 28: 2025-2025. DOI: 10.1200/Jco.2010.28.15_Suppl.2025  0.403
2010 Ezhilarasan R, Goodman LD, Love PN, Aldape KD, Sulman EP. Abstract 5157: Functional and regulatory role of src kinase in podoplanin expressing glioma cancer stem cells Cancer Research. 70: 5157-5157. DOI: 10.1158/1538-7445.Am10-5157  0.408
2010 Love PN, Ezhilarasan R, Goodman LD, Aldape KD, Sulman EP. Abstract 5147: Trancriptional activation of the glioma stem cell marker podoplanin by the homeobox transcription factor prox1 Cancer Research. 70: 5147-5147. DOI: 10.1158/1538-7445.Am10-5147  0.393
2010 Goodman LD, Gao F, Gumin J, Villareal D, Ezhilarasan R, Love P, Colman H, Lang FF, Aldape KD, Sulman EP. Abstract 4305: Refinement of the glioma cancer stem cell marker profile Cancer Research. 70: 4305-4305. DOI: 10.1158/1538-7445.Am10-4305  0.354
2010 Bredel M, Yadav A, Renfrow J, Scholtens D, Chandler J, Bredel C, Tagge M, Lukac P, Robe P, Vogel H, Scheck A, Aldape K, Chakravarti A, Harsh G. Abstract 1789: NFKBIA deletion in malignant gliomas Cancer Research. 70: 1789-1789. DOI: 10.1158/1538-7445.Am10-1789  0.45
2010 Salazar K, Balasubramaniyan V, Vaillant B, Hollingsworth F, Diefes K, Patel D, Bhat K, Aldape K. Abstract B27: TAZ as a regulator of mesenchymal transformation and clinical aggressiveness in gliomas Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B27  0.437
2009 Gilbert MR, Wang M, Aldape K, Lassman A, Sorensen AG, Mikkelson T, Groves M, Werner-Wasik M, Regine W, Mehta M. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2011. PMID 27964588 DOI: 10.1200/Jco.2009.27.15_Suppl.2011  0.38
2009 Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7538-7546. PMID 19996208 DOI: 10.1158/1078-0432.Ccr-09-1985  0.389
2009 Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, Mehdorn HM, Davis G, Steinberg SM, Meltzer PS, Aldape K, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Molecular Cancer Research : McR. 7: 1438-45. PMID 19723875 DOI: 10.1158/1541-7786.Mcr-09-0234  0.352
2009 Zhao X, D' Arca D, Lim WK, Brahmachary M, Carro MS, Ludwig T, Cardo CC, Guillemot F, Aldape K, Califano A, Iavarone A, Lasorella A. The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Developmental Cell. 17: 210-21. PMID 19686682 DOI: 10.1016/J.Devcel.2009.07.009  0.31
2009 Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4829-37. PMID 19622585 DOI: 10.1158/1078-0432.Ccr-08-2921  0.383
2009 Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4622-9. PMID 19584161 DOI: 10.1158/1078-0432.Ccr-08-3012  0.344
2009 Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Seminars in Radiation Oncology. 19: 142-9. PMID 19464628 DOI: 10.1016/J.Semradonc.2009.02.001  0.451
2009 Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-year survival in glioblastoma: a case report and molecular profile. International Journal of Radiation Oncology, Biology, Physics. 75: 1162-5. PMID 19327897 DOI: 10.1016/J.Ijrobp.2008.12.054  0.305
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, ... ... Aldape K, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  0.367
2009 Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Therapy. 16: 256-65. PMID 18927600 DOI: 10.1038/Cgt.2008.75  0.33
2009 Sulman EP, Eifel PJ, Jhingran A, Aldape KD, Deavers MT, Klopp AH. Podoplanin Expression is Prognostic for Survival of Patients with Squamous Cell Carcinoma of the Cervix Treated with Definitive Radiation Therapy International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.850  0.308
2009 Ezhilarasan R, Love PN, Goodman LD, Aldape KD, Sulman EP. Expression of c-met in Human Glioblastoma Does Not Correlate with Patient Survival or Clinical Radiation Response International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.581  0.313
2008 Shreeve SM, Palmieri D, Johnson MM, Aldape KD, Davis S, Meltzer PS, Davis GL, Hoffmann CM, Steinberg SM, Steeg PS. Correlation of hexokinase-2 expression with overall survival and potential as a therapeutic target in the treatment of breast cancer brain metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1005. PMID 27951392 DOI: 10.1200/Jco.2008.26.15_Suppl.1005  0.354
2008 Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. Plos One. 3: e4076. PMID 19115005 DOI: 10.1371/Journal.Pone.0004076  0.341
2008 McDonald JM, Pelioski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung Clinical Cancer Research. 14: 7832-7837. PMID 19047111 DOI: 10.1158/1078-0432.Ccr-08-0565  0.374
2008 Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro-Oncology. 10: 940-5. PMID 18708344 DOI: 10.1215/15228517-2008-061  0.371
2008 Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, Aldape KD. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. Febs Letters. 582: 3193-200. PMID 18708058 DOI: 10.1016/J.Febslet.2008.08.010  0.301
2008 Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Jama Neurology. 65: 877-883. PMID 18625854 DOI: 10.1001/Archneur.65.7.877  0.347
2008 de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 90: 89-97. PMID 18581057 DOI: 10.1007/S11060-008-9637-Y  0.359
2008 Sulman EP, Aldape K, Colman H. Brain tumor stem cells. Current Problems in Cancer. 32: 124-142. PMID 18501775 DOI: 10.1016/J.Currproblcancer.2008.02.004  0.339
2008 Rivera AL, Pelloski CE, Sulman E, Aldape K. Prognostic and predictive markers in glioma and other neuroepithelial tumors. Current Problems in Cancer. 32: 97-123. PMID 18501774 DOI: 10.1016/J.Currproblcancer.2008.02.003  0.375
2008 Cheung HC, Baggerly KA, Tsavachidis S, Bachinski LL, Neubauer VL, Nixon TJ, Aldape KD, Cote GJ, Krahe R. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. Bmc Genomics. 9: 216. PMID 18474104 DOI: 10.1186/1471-2164-9-216  0.378
2008 Fischer I, de la Cruz C, Rivera AL, Aldape K. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 17: 227-30. PMID 18382350 DOI: 10.1097/Pdm.0B013E3181642230  0.302
2008 Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology (Zurich, Switzerland). 18: 360-9. PMID 18371182 DOI: 10.1111/J.1750-3639.2008.00129.X  0.371
2008 Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, Kuo MD. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proceedings of the National Academy of Sciences of the United States of America. 105: 5213-8. PMID 18362333 DOI: 10.1073/Pnas.0801279105  0.42
2008 Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, ... Aldape KD, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 10: 162-70. PMID 18356283 DOI: 10.1215/15228517-2007-062  0.413
2008 Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathologica. 116: 79-86. PMID 18351367 DOI: 10.1007/S00401-008-0359-1  0.35
2008 Davis FG, Malmer BS, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brännström T, Bruner JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, et al. Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 484-9. PMID 18349266 DOI: 10.1158/1055-9965.Epi-07-0725  0.38
2008 Xie TX, Aldape KD, Gong W, Kanzawa T, Suki D, Kondo S, Lang F, Ali-Osman F, Sawaya R, Huang S. Aberrant NF-κB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor International Journal of Oncology. 33: 5-15. DOI: 10.3892/Ijo.33.1.5  0.321
2008 Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, Conrad CA, Madden T, Yung A, Priebe W. Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells Journal of Clinical Oncology. 26: 2003-2003. DOI: 10.1200/Jco.2008.26.15_Suppl.2003  0.317
2008 Lang FF, Gumin J, Amano T, Hata N, Heimberger AB, Marini F, Andreeff M, Aldape KD, Sulman E, Colman H. Tumor-derived mesenchymal stem cells in human gliomas: Isolation and biological properties Journal of Clinical Oncology. 26: 2001-2001. DOI: 10.1200/Jco.2008.26.15_Suppl.2001  0.349
2008 Sulman EP, Pelloski CE, Aldape KD. Analysis of Patients Receiving Histone Deacetylase Inhibiting Antiepileptic Agents during Radiation Treatment for Glioblastoma International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.696  0.326
2008 McGovern SL, Aldape KD, Munsell MF, Woo SY. Recurrence-free Survival in Meningioma Patients Receiving Radiation International Journal of Radiation Oncology Biology Physics. 72. DOI: 10.1016/J.Ijrobp.2008.06.621  0.3
2007 Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6603-9. PMID 18006760 DOI: 10.1158/1078-0432.Ccr-07-0145  0.402
2007 Levin VA, Jochec JL, Shantz LM, Aldape KD. Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy. International Journal of Cancer. Journal International Du Cancer. 121: 2279-83. PMID 17582600 DOI: 10.1002/Ijc.22914  0.412
2007 Hong C, Moorefield KS, Jun P, Aldape KD, Kharbanda S, Phillips HS, Costello JF. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proceedings of the National Academy of Sciences of the United States of America. 104: 10974-9. PMID 17578925 DOI: 10.1073/Pnas.0700683104  0.397
2007 Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Research. 67: 4190-8. PMID 17483330 DOI: 10.1158/0008-5472.Can-06-3316  0.342
2007 Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Research. 67: 4005-9. PMID 17483310 DOI: 10.1158/0008-5472.Can-06-2973  0.375
2007 Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma Proceedings of the National Academy of Sciences of the United States of America. 104: 3466-3471. PMID 17360667 DOI: 10.1073/Pnas.0611271104  0.333
2007 Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Archives of Pathology & Laboratory Medicine. 131: 242-51. PMID 17284109 DOI: 10.1043/1543-2165(2007)131[242:Caoqla]2.0.Co;2  0.301
2007 Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Research. 67: 890-900. PMID 17283119 DOI: 10.1158/0008-5472.Can-06-0973  0.389
2007 Puchades M, Nilsson CL, Emmett MR, Aldape KD, Ji Y, Lang FF, Liu TJ, Conrad CA. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. Journal of Proteome Research. 6: 869-75. PMID 17269744 DOI: 10.1021/Pr060302L  0.407
2007 Chakravarti A, Tyndall E, Palanichamy K, Mehta M, Aldape KD, Loeffler J. Impact of molecular profiling on clinical trial design for glioblastoma. Current Oncology Reports. 9: 71-79. PMID 17164051 DOI: 10.1007/Bf02951429  0.306
2007 Groot JFD, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C, Aldape K, Colman H, Puduvalli V, Yung WA. Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 25: 2024-2024. DOI: 10.1200/Jco.2007.25.18_Suppl.2024  0.399
2007 Bredel M, Phillips H, Harsh GR, Aldape K, Sikic BI. A regulatory network of canonical nuclear factor-κB activation predicts high-grade glioma outcome Journal of Clinical Oncology. 25: 2007-2007. DOI: 10.1200/Jco.2007.25.18_Suppl.2007  0.361
2006 Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Molecular Cancer Research : McR. 4: 915-26. PMID 17189382 DOI: 10.1158/1541-7786.Mcr-06-0184  0.351
2006 Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, ... ... Aldape K, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4899-907. PMID 16914578 DOI: 10.1158/1078-0432.Ccr-06-0773  0.34
2006 Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, ... ... Aldape K, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3651-6. PMID 16877733 DOI: 10.1200/Jco.2006.06.2323  0.325
2006 Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia (New York, N.Y.). 8: 419-28. PMID 16790091 DOI: 10.1593/Neo.06109  0.37
2006 Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. The American Journal of Surgical Pathology. 30: 657-64. PMID 16699322 DOI: 10.1097/01.Pas.0000202048.28203.25  0.361
2006 Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. Journal of Neuro-Oncology. 80: 83-90. PMID 16639492 DOI: 10.1007/S11060-006-9160-Y  0.332
2006 Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. Bmc Cancer. 6: 97. PMID 16623952 DOI: 10.1186/1471-2407-6-97  0.398
2006 Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, Aldape K, Sawaya R, Bruner JM, Fuller GN, Zhang W. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics. 6: 2964-71. PMID 16619307 DOI: 10.1002/Pmic.200500555  0.314
2006 Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, Aldape KD, Lamborn KR, Parsa AT, Sison JD, Prados MD. Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival Cancer Research. 66: 4531-4541. PMID 16618782 DOI: 10.1158/0008-5472.Can-05-4032  0.417
2006 Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, Sawaya R, Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Research. 66: 3593-602. PMID 16585184 DOI: 10.1158/0008-5472.Can-05-2912  0.374
2006 Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1627-32. PMID 16575014 DOI: 10.1200/Jco.2005.04.0402  0.344
2006 Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Research. 66: 3188-96. PMID 16540670 DOI: 10.1158/0008-5472.Can-05-2674  0.305
2006 Su X, Gopalakrishnan V, Stearns D, Aldape K, Lang FF, Fuller G, Snyder E, Eberhart CG, Majumder S. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Molecular and Cellular Biology. 26: 1666-78. PMID 16478988 DOI: 10.1128/Mcb.26.5.1666-1678.2006  0.348
2006 Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area Neuro-Oncology. 8: 12-26. PMID 16443944 DOI: 10.1215/S1522851705000268  0.341
2006 Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 107: 3716-23. PMID 16418334 DOI: 10.1182/Blood-2005-03-0897  0.373
2006 McDonald JM, Dunlap S, Cogdell D, Dunmire V, Wei Q, Starzinski-Powitz A, Sawaya R, Bruner J, Fuller GN, Aldape K, Zhang W. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biology & Therapy. 5: 300-4. PMID 16410724 DOI: 10.4161/Cbt.5.3.2391  0.345
2006 Issa S, Hwang J, Karch J, Fridlyand J, Prados M, Batchelor T, Aldape K, Haqq C, Damon L, Rubenstein J. Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis Journal of Clinical Oncology. 24: 7595-7595. DOI: 10.1200/Jco.2006.24.18_Suppl.7595  0.305
2006 Ibrahim NK, Nguyen G, Suki D, Hennessy B, Montero A, Sarriera JE, Symmans F, Valero V, Sawaya R, Aldape K. Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM) Journal of Clinical Oncology. 24: 656-656. DOI: 10.1200/Jco.2006.24.18_Suppl.656  0.328
2006 Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM Journal of Clinical Oncology. 24: 2529-2529. DOI: 10.1200/Jco.2006.24.18_Suppl.2529  0.393
2006 Olson MV, Aldape KD, Fuller GN, Alonso MM, Gomez-Manzano C, David JG, Juan F. 320. Modeling Human Brain Cancer in Transgenic E2F1 Mice Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.377  0.394
2006 Aldape K, Colman H, James CD. Models of malignant glioma Drug Discovery Today: Disease Models. 3: 191-196. DOI: 10.1016/J.Ddmod.2006.06.002  0.321
2005 Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD. The molecular epidemiology of gliomas in adults. Neurosurgical Focus. 19: E5. PMID 16398469 DOI: 10.3171/Foc.2005.19.5.6  0.424
2005 Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. Journal of the National Cancer Institute. 97: 1589-600. PMID 16264179 DOI: 10.1093/Jnci/Dji340  0.384
2005 Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients Journal of Translational Medicine. 3: 38-38. PMID 16236164 DOI: 10.1186/1479-5876-3-38  0.346
2005 Marsit CJ, Wiencke JK, Nelson HH, Kim DH, Hinds PW, Aldape K, Kelsey KT. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genetics and Cytogenetics. 162: 115-21. PMID 16213358 DOI: 10.1016/J.Cancergencyto.2005.04.001  0.35
2005 Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, Aldape KD, McMillan A, Wiemels J, Wiencke JK. ERCC1 and ERCC2 polymorphisms and adult glioma Neuro-Oncology. 7: 495-507. PMID 16212814 DOI: 10.1215/S1152851705000037  0.341
2005 McDonald JM, Dunmire V, Taylor E, Sawaya R, Bruner J, Fuller GN, Aldape K, Zhang W. Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. Molecular Cancer. 4: 35. PMID 16156899 DOI: 10.1186/1476-4598-4-35  0.367
2005 Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathology. 36: 768-76. PMID 16084946 DOI: 10.1016/J.Humpath.2005.05.006  0.399
2005 Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, Kelsey KT, Patoka J, Long J, Wrensch M. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1774-83. PMID 16030116 DOI: 10.1158/1055-9965.Epi-05-0089  0.331
2005 Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/S10637-005-1444-0  0.341
2005 Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3326-34. PMID 15867231 DOI: 10.1158/1078-0432.Ccr-04-1765  0.387
2005 Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America. 102: 5814-9. PMID 15827123 DOI: 10.1073/Pnas.0402870102  0.417
2005 Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, Aldape KD. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Research. 65: 1678-86. PMID 15753362 DOI: 10.1158/0008-5472.Can-04-2921  0.387
2005 Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1462-6. PMID 15746047 DOI: 10.1158/1078-0432.Ccr-04-1737  0.333
2005 Pelloski CE, Yung WA, Colman H, Zhang L, Lin E, Woo SY, Yang H, Ledoux A, Aldape KD. EGFRvIII Expression Defines a Distinct Subtype of Glioblastoma: A Study of 268 Patients International Journal of Radiation Oncology Biology Physics. 63. DOI: 10.1016/J.Ijrobp.2005.07.118  0.313
2004 Marsit CJ, Hasegawa M, Hirao T, Kim DH, Aldape K, Hinds PW, Wiencke JK, Nelson HH, Kelsey KT. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. Cancer Research. 64: 8702-7. PMID 15574780 DOI: 10.1158/0008-5472.Can-04-2558  0.355
2004 Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. Journal of Neuropathology and Experimental Neurology. 63: 700-7. PMID 15290895 DOI: 10.1093/Jnen/63.7.700  0.424
2004 Bohinski RJ, Mendel E, Aldape KD, Rhines LD. Intramedullary and extramedullary solitary fibrous tumor of the cervical spine. Case report and review of the literature. Journal of Neurosurgery. 100: 358-63. PMID 15070144 DOI: 10.3171/Spi.2004.100.4.0358  0.364
2004 Pandita A, Aldape KD, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes, Chromosomes & Cancer. 39: 29-36. PMID 14603439 DOI: 10.1002/Gcc.10300  0.318
2004 Buckner JC, Aldape KD, Ballman K, Scheithauer BW, Burger PC, Giannini C, Schaefer PL, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials Journal of Clinical Oncology. 22: 1508-1508. DOI: 10.1200/Jco.2004.22.90140.1508  0.429
2003 Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2508-18. PMID 12839017 DOI: 10.1200/Jco.2003.21.13.2508  0.325
2003 Lee HK, Chang EL, Fuller GN, Aldape KD, Atkinson GJ, Levy LB, McCutcheon IE, Maor MH. The prognostic value of neurologic function in astrocytic spinal cord glioma. Neuro-Oncology. 5: 208-13. PMID 12816727 DOI: 10.1215/S1152851702000595  0.363
2003 Schmidt MH, Berger MS, Lamborn KR, Aldape K, McDermott MW, Prados MD, Chang SM. Repeated operations for infiltrative low-grade gliomas without intervening therapy. Journal of Neurosurgery. 98: 1165-9. PMID 12816258 DOI: 10.3171/Jns.2003.98.6.1165  0.397
2003 Aldape KD, Okcu MF, Bondy ML, Wrensch M. Molecular epidemiology of glioblastoma. Cancer Journal (Sudbury, Mass.). 9: 99-106. PMID 12784875 DOI: 10.1097/00130404-200303000-00005  0.366
2003 Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 101: 466-8. PMID 12393404 DOI: 10.1182/Blood-2002-06-1636  0.306
2002 Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, ... ... Aldape K, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene. 21: 7453-63. PMID 12386807 DOI: 10.1038/Sj.Onc.1205936  0.394
2002 Katsetos CD, Del Valle L, Geddes JF, Aldape K, Boyd JC, Legido A, Khalili K, Perentes E, Mörk SJ. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. Journal of Neuropathology and Experimental Neurology. 61: 307-20. PMID 11939586 DOI: 10.1093/Jnen/61.4.307  0.371
1998 Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control Proceedings of the National Academy of Sciences of the United States of America. 95: 5166-5171. PMID 9560247 DOI: 10.1073/Pnas.95.9.5166  0.322
1997 Barker FG, Chen P, Furman F, Aldape KD, Edwards MS, Israel MA. P16 deletion and mutation analysis in human brain tumors. Journal of Neuro-Oncology. 31: 17-23. PMID 9049826 DOI: 10.1023/A:1005768910871  0.36
Show low-probability matches.